このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

集団レベルにおける消化管通過時間に関する研究 (GITTPop)

2026年11月10日 更新者:Christophe Matthys、KU Leuven

集団レベルにおける胃腸通過時間:横断研究

The goal of this study is to investigate the baseline of gastrointestinal transit time (GITT) and explore its relationship with other health indicators in 932 healthy adult volunteers.

The main questions it aims to answer are:

What are the population-level baseline values for GITT using the blue dye method? How is GITT associated with key physiological parameters including blood metabolic markers, life style, and stool characteristics?

Participants will:

Consume a standardized blue dye muffin after overnight fasting at the research center; Offer a finger prock blood samples for metabolic profiling; Offer a saliva sample for whole exome sequencing analysis; Collect stool samples for moisture measurement; Complete detailed questionnaires on diet, lifestyle, and bowel habits; Record the time of first blue stool appearance to determine GITT.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

This explorative study is designed as a cross-sectional investigation aimed at establishing population-level reference values for gastrointestinal transit time (GITT). Adult participants from the general population will undergo GITT measurement using the blue-dye method. This muffin contains blue colorant that cannot be absorbed; after ingestion, it passes through the entire gastrointestinal tract and is eventually excreted in feces. Following a two-day lifestyle standardization period (including dietary and activity guidance) to minimize potential confounding effects on gastrointestinal motility, participants will attend a clinical visit where they will ingest a blue muffin. GITT will be determined by measuring both the time interval between ingestion of the blue muffin and the first appearance of blue-colored stool, and the duration from its first appearance to its complete disappearance.

The blue muffin method has been well-established in previous research for GITT assessment. Building upon the methodology developed by Berry et al., we will introduce stricter pre-test condition controls (includes dietary advice and lifestyle recommendations) and optimized the blue muffin formulation. These improvements allow for reliable measurement with a single muffin administration, which has been evaluated through KU Leuven Health Pass in a large sample size(S-70168).

To investigate potential determinants and correlates of GITT, we will collect biochemical parameters, fecal moisture, and resting metabolic rate. We will collect saliva samples for WGS to identify key genetic variants associated with GITT and use these findings to develop a genetic risk score. Additionally, participants will complete 24-h diet record and health questionnaires assessing bowel movement, physical activity habits, stress levels, sleep quality and hydration condition for subsequent correlation analyses.

研究の種類

観察的

入学 (推定)

932

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Flemish Brabant
      • Leuven、Flemish Brabant、ベルギー、3000

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Healthy volunteers from the Flanders region who volunteered to participate in the research

説明

Inclusion Criteria:

  1. 18-65 years old
  2. 18.5 kg/m² ≤ BMI ≤ 25 kg/m² or BMI ≥ 30 kg/m² (people with normal weight or obesity)
  3. Provision of informed consent to participate.

Exclusion Criteria:

  1. Gastrointestinal conditions which may affect nutrient absorption or gastric emptying, including coeliac disease, Crohn's disease, previous resection of the small intestine other than bariatric surgery, gastroparesis;
  2. Using medications which effect gastric motility (e.g., domperidone, erythromycin, metoclopramide, prucalopride, opiates, loperamide, …)
  3. The ingredients of blue muffins include gluten, nuts, baking powder, sugar, vanilla extract and sunflower oil. Participants with allergies to these ingredients;
  4. Current diagnosis of cancer;
  5. Advanced organ failure, including chronic kidney disease Stage 5, liver cirrhosis Child-Pugh B or C, intestinal failure, heart failure stage D, or chronic obstructive pulmonary disease stage 4;
  6. Immobility;
  7. Neuromuscular degenerative conditions associated with muscular atrophy, such as myasthenia gravis, muscular dystrophies, fibromyalgia, or multiple Sclerosis;

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:CROSS_SECTIONAL

コホートと介入

グループ/コホート
介入・治療
Adult participants

Healthy adult participants without serious gastrointestinal diseases

Participants will consume a regular muffin containing blue dye

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Gastrointestinal transit time
時間枠:From enrollment to the end of study at 2 weeks

Calculate the transit time by the recorded muffin consuming time, first blue stool appearance time and last blue stool appearance time

From enrollment to the end of study at 2 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Height (cm)
時間枠:baseline

Measured using a height meter, in centimeters.

baseline
Weight (kg)
時間枠:baseline

Measuring using a scale, in kg.

baseline
BMI
時間枠:baseline

weight and height will be combined to report BMI in kg/m^2

baseline
Blood glucose (mmol/L)
時間枠:baseline

Measure blood glucose by CardioChek Plus in mmol/L

baseline
Fat mass (kg)
時間枠:baseline

Using Bodystat quadscan 4000 to measure fat mass (kg)

baseline
Lean body mass(kg)
時間枠:baseline

Using Bodystat quadscan 4000 to measure lean body mass (kg)

baseline
Fat percentage (%)
時間枠:baseline

Using Bodystat quadscan 4000 to measure fat%

baseline
Total cholesterol (mmol/L)
時間枠:baseline

Measuring by Mission cholesterol Meter in mmol/L

baseline
HDL-C (mmol/L)
時間枠:baseline

Measuring by Mission cholesterol Meter in mmol/L

baseline
LDL-C (mmol/L)
時間枠:baseline

Measuring by Mission cholesterol Meter in mmol/L

baseline
Triglyceride (mmol/L)
時間枠:baseline

Measuring by Mission Cholesterol Meter in mmol/L

baseline
Food record
時間枠:2 days after study

Participants record their 24-h diets through smartphone application

2 days after study
Stool form
時間枠:baseline

Stool form will be evaluated by Bristol Stool Form Scale, the score is from 1 to 7, with values closer to the middle indicating more ideal stool shape.

baseline
Hydration status
時間枠:baseline

Hydration status will be rated from 1 to 8 by Urine color chart, with higher numbers indicating that the body needs more water.

baseline
Perceived level of stress
時間枠:baseline

The10-item Perceived Stress will be used to measures an individual's perceived level of stress over the past month. The total score ranges from 0 to 40. A higher score indicates a greater perceived level of stress.

baseline
Sleep quality
時間枠:baseline

Pittsburgh Sleep Quality Index will be used to assess subjective sleep quality over the past month. The total score ranges from 0 to 21. A higher score indicates poorer sleep quality.

baseline
Activity level
時間枠:baseline

The Baecke Physical Activity Questionnaire will be used to assess daily habitual physical activity, with a particular focus on work-related and exercise-related activities. It does not produce a single total score, but rather scores on three dimensions, each typically ranging from 1 to 5. On each dimension, a higher score indicates a higher level of physical activity in that area. Therefore, for assessing activity levels, a higher score is generally better.

baseline
Whole genome sequencing (WGS)
時間枠:baseline

The genetic risk score will be calculated by summing the number of GITT-associated alleles carried by each participant, weighted by their estimated effect sizes. As the number and weights of the included variants will be determined during the analysis, the score does not have a predefined numerical range. The score will be standardized to a mean of 0 and a standard deviation of 1. A higher score will indicate a stronger genetic predisposition to the GITT phenotype of interest; it does not necessarily represent a better or worse health outcome.

baseline

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年12月1日

一次修了 (推定)

2026年12月30日

研究の完了 (推定)

2026年12月30日

試験登録日

最初に提出

2025年11月17日

QC基準を満たした最初の提出物

2025年12月15日

最初の投稿 (実際)

2025年12月30日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月13日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • S70908

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。